{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:18:11Z","timestamp":1783203491682,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.03.032","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:51:09Z","timestamp":1778719869000},"page":"1268-1276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.032_bib0001","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","article-title":"The many faces of psoriatic arthritis: their genetic determinism","volume":"59","author":"Winchester","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2026.03.032_bib0002","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/kead284","article-title":"Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries","volume":"63","author":"Linde","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ard.2026.03.032_bib0003","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s10067-024-07193-y","article-title":"Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis","volume":"43","author":"Kunzler","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.ard.2026.03.032_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis","volume":"72","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 3","key":"10.1016\/j.ard.2026.03.032_bib0005","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.2007.079798","article-title":"Minimal clinically important improvement\/difference (MCII\/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?","volume":"66","author":"Kvien","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.03.032_bib0006","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/acr.25111","article-title":"Responsiveness and minimum clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis: a prospective cohort study","volume":"75","author":"Karmacharya","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2026.03.032_bib0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3899\/jrheum.2023-0764","article-title":"Patient-reported outcomes (PROs) and PRO remission rates in 12,262 biologic-naive patients with psoriatic arthritis treated with tumor necrosis factor inhibitors in routine care","volume":"51","author":"Ornbjerg","year":"2024","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.032_bib0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/art.24282","article-title":"Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline","volume":"61","author":"Aletaha","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ard.2026.03.032_bib0009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.ard.2026.03.032_bib0010","first-page":"138","article-title":"Patient profiles in randomized controlled trials versus a real-world study in psoriatic arthritis: scoping review and metaanalysis","volume":"52","author":"Alle","year":"2025","journal-title":"J Rheumatol"},{"issue":"10230","key":"10.1016\/j.ard.2026.03.032_bib0011","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-na\u00efve or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.ard.2026.03.032_bib0012","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-na\u00efve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ard.2026.03.032_bib0013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.03.032_bib0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.03.032_bib0015","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3899\/jrheum.140172","article-title":"Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response","volume":"41","author":"Helliwell","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.032_bib0016","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.03.032_bib0017","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1093\/rheumatology\/keac025","article-title":"Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis","volume":"61","author":"Mulder","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.032_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/annrheumdis-2021-eular.1622","article-title":"OP0224 Continuous composite measures for routine care in psoriatic arthritis: thresholds of meaning and clinically important difference estimates for the 3 and 4 VAS scales from a UK multicentre study","volume":"80","author":"Tillett","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.032_bib0019","series-title":"General Methods","first-page":"174","year":"2022"},{"issue":"11","key":"10.1016\/j.ard.2026.03.032_bib0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ard.2026.03.032_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s41687-019-0115-4","article-title":"Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis","volume":"3","author":"Cella","year":"2019","journal-title":"J Patient Rep Outcomes"},{"issue":"4","key":"10.1016\/j.ard.2026.03.032_bib0022","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.03.032_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"10.1016\/j.ard.2026.03.032_bib0024","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.032_bib0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"Copay","year":"2007","journal-title":"Spine J."},{"issue":"2","key":"10.1016\/j.ard.2026.03.032_bib0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"issue":"5","key":"10.1016\/j.ard.2026.03.032_bib0027","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.ard.2026.03.032_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.032_bib0029","article-title":"Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale","volume":"2011","author":"Stauffer","year":"2011","journal-title":"Int J Inflam"},{"key":"10.1016\/j.ard.2026.03.032_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.07.015","article-title":"Baseline health status and setting impacted minimal clinically important differences in COPD: an exploratory study","volume":"116","author":"Alma","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ard.2026.03.032_bib0031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.ard.2026.03.032_bib0032","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/art.22110","article-title":"Feeling good rather than feeling better matters more to patients","volume":"55","author":"Tubach","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2026.03.032_bib0033","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2522\/ptj.20100229","article-title":"Baseline dependency of minimal clinically important improvement","volume":"91","author":"Wang","year":"2011","journal-title":"Phys Ther"},{"issue":"6","key":"10.1016\/j.ard.2026.03.032_bib0034","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40744-024-00702-0","article-title":"Early improvements with guselkumab associate with sustained control of psoriatic arthritis: post hoc analyses of two phase 3 trials","volume":"11","author":"Curtis","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.ard.2026.03.032_bib0035","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/rheumatology\/keae586","article-title":"Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS","volume":"64","author":"Gossec","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.03.032_bib0036","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:13:06Z","timestamp":1783203186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0003496726002220"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.032","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}